At the time of writing, Annovis Bio Inc [ANVS] stock is trading at $2.43, up 15.17%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ANVS shares have gain 19.12% over the last week, with a monthly amount glided 44.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Annovis Bio Inc [NYSE: ANVS] stock has seen the most recent analyst activity on February 10, 2025, when D. Boral Capital downgraded its rating to a Hold. Previously, Maxim Group upgraded its rating to Buy on October 25, 2024, and kept the price target unchanged to $25. On December 29, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $36 on the stock. Maxim Group reiterated its Buy rating and increased its price target to $150 on July 07, 2021.
For the past year, the stock price of Annovis Bio Inc fluctuated between $1.11 and $7.80. Currently, Wall Street analysts expect the stock to reach $25.67 within the next 12 months. Annovis Bio Inc [NYSE: ANVS] shares were valued at $2.43 at the most recent close of the market. An investor can expect a potential return of 956.38% based on the average ANVS price forecast.
Analyzing the ANVS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.01 and Total Capital is -0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.24 points at the first support level, and at 2.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.56, and for the 2nd resistance point, it is at 2.68.
Ratios To Look Out For
It is important to note that Annovis Bio Inc [NYSE:ANVS] has a current ratio of 7.65. In addition, the Quick Ratio stands at 7.65 and the Cash Ratio stands at 6.11.
Transactions by insiders
Recent insider trading involved Maccecchini Maria-Luisa, President & CEO, that happened on Oct 28 ’25 when 97561.0 shares were purchased. Director, Hoffman Michael B completed a deal on Oct 28 ’25 to buy 0.98 million shares.
